The Specimen Resource Core is the cornerstone of all Yale SPORE in Skin Cancer (YSPORE) activities. It addresses the broad melanoma patient specimen needs of all the projects that are not met by current shared facilities at Yale. The core goes beyond fulfilling the required duties of a Specimen Resource Core delineated by the SPORE guidelines. In addition to collecting, storing and distributing a wide range of specimens and reagents, the core performs quality assurance testing and a wide range of molecular analyses of specimens. More specifically, the core: a) collects a large repertoire of specimens for translational and preclinical studies in melanoma, including melanocytic lesions, melanoma tumors and cells, normal skin, serum, and circulating lymphocytes;b) ensures high quality control and proper long-term storage, annotation, and timely distribution of specimens to YSPORE investigators;c) establishes and maintains a central database of essential pathological, clinical, epidemiological, follow-up information and basic research data generated by the YSPORE projects that is integrated with the Bioinformatics/Biostatistics Core;d) provides special, services such as the analysis of specimens from clinical trials, mutations, chromatin modification, and collection of TlLs (tumor infiltrating lymphocytes;e) maintains and distributes validated reagents (antibodies, oligonucleotides for PCR, DNA, RNA, plasmids, cell extracts) needed for molecular analyses of tumors by different YSPORE investigators;f) establishes links with shared facilities at Yale and similar resources in other institutions, including other SPOREs and sends out samples to collaborating investigators outside of Yale;and g) provides specimens for larger NCI objectives, including melanoma specimens, peripheral blood lymphocytes, and annotated clinical data for The Cancer Genome Atlas (TCGA). The core Interacts extensively with investigators in each project, the Bioinformatics, Clinical Trial Office, Immunology, Critical Technologies for Tissue Services, and Genetics shared facilities of the Yale Comprehensive Cancer Center. The services of the Specimen Resource Core enhance the efficient operation of the translational studies by YSPORE investigators in a cost-effective manner, and expedite the application of discoveries at the bench to clinical practice, and clinical results to basic research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA121974-06A1
Application #
8389781
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2006-06-01
Project End
2017-08-31
Budget Start
2012-09-19
Budget End
2013-08-31
Support Year
6
Fiscal Year
2012
Total Cost
$167,269
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ferrucci, Leah M; Cartmel, Brenda; Clare, Rachel A et al. (2018) Cross-sectional assessment of ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma. J Am Acad Dermatol 79:149-152
Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533
Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Sulkowski, Parker L; Scanlon, Susan E; Oeck, Sebastian et al. (2018) PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Mol Cancer Res 16:1241-1254
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Krauthammer, Michael (2018) Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 10:S1074-S1075
Das, Rituparna; Bar, Noffar; Ferreira, Michelle et al. (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715-720
Miller, Chad J; Muftuoglu, Yagmur; Turk, Benjamin E (2017) A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochem Pharmacol 142:39-45
Kluger, Harriet M; Zito, Christopher R; Turcu, Gabriela et al. (2017) PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 23:4270-4279

Showing the most recent 10 out of 172 publications